# Molecular Mechanisms of Cardiac Fibrosis: A Pathologist’s Perspective

## TL;DR

This paper reviews how heart fibrosis develops at the molecular level and highlights the role of pathologists in linking these mechanisms to diagnosis and treatment.

## Contribution

The paper integrates molecular signaling pathways with histopathological findings to provide a comprehensive view of cardiac fibrosis.

## Key findings

- Cardiac fibrosis involves activation of fibroblasts via TGF-β, Wnt/β-catenin, and Hippo-YAP/TAZ pathways.
- Neurohumoral mediators like angiotensin II and aldosterone increase extracellular matrix synthesis and tissue stiffness.
- Epigenetic modulators and non-coding RNAs sustain fibroblast activation and matrix remodeling.

## Abstract

Cardiac fibrosis represents a final common pathway in a wide range of cardiac disorders, leading to structural remodeling, diastolic dysfunction, and heart failure. From a pathologist’s viewpoint, fibrotic remodeling displays distinctive morphologic patterns such as interstitial, perivascular, and replacement fibrosis, which mirror specific cellular and molecular mechanisms. Central to this process is the activation of cardiac fibroblasts into myofibroblasts, driven by profibrotic signaling cascades such as transforming growth factor beta (TGF-β)/mothers against decapentaplegic homolog proteins (SMAD), Wingless/Integrated signaling pathway (Wnt)/βeta-catenin, and Hippo-Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) pathways. Neurohumoral mediators, including angiotensin II and aldosterone, further amplify extracellular matrix synthesis and tissue stiffness. Epigenetic modulators and non-coding RNAs (n-c RNAs) orchestrate transcriptional programs that perpetuate fibroblast activation. Histopathological correlates of these molecular events, collagen deposition, alpha-smooth muscle actin (α-SMA) expression, and extracellular matrix (ECM) cross-linking, can be demonstrated through immunohistochemistry and digital morphometry. This review integrates molecular signaling and morphologic evidence to delineate the mechanisms of cardiac fibrosis, emphasizing the pathologist’s role as a link between molecular insight and diagnostic interpretation. Understanding these intertwined processes provides the foundation for novel antifibrotic therapies targeting key molecular nodes of fibroblast activation and matrix remodeling.